

Takayuki Ueno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6740880/publications.pdf>

Version: 2024-02-01

93
papers

1,376
citations

516710

16
h-index

377865

34
g-index

95
all docs

95
docs citations

95
times ranked

2011
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530. | 10.7 | 441 |
| 2 | Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1298-1306. | 6.3 | 83 |
| 3 | Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588. | 7.0 | 73 |
| 4 | Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. <i>Cancer Science</i> , 2013, 104, 1539-1543. | 3.9 | 65 |
| 5 | HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. <i>BMC Medicine</i> , 2022, 20, 105. | 5.5 | 60 |
| 6 | Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 607-613. | 2.2 | 54 |
| 7 | Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. <i>Cancer Science</i> , 2011, 102, 858-865. | 3.9 | 44 |
| 8 | Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. <i>BMC Cancer</i> , 2016, 16, 230. | 2.6 | 30 |
| 9 | Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559. | 2.5 | 29 |
| 10 | Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 1-25. | 2.6 | 29 |
| 11 | Serial measurement of serum S-100B protein as a marker of cerebral damage after cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2003, 75, 1892-1897. | 1.3 | 28 |
| 12 | Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. <i>European Journal of Cancer</i> , 2011, 47, 2265-2272. | 2.8 | 27 |
| 13 | Risk Factors for Skin Flap Necrosis in Breast Cancer Patients Treated with Mastectomy Followed by Immediate Breast Reconstruction. <i>World Journal of Surgery</i> , 2019, 43, 846-852. | 1.6 | 24 |
| 14 | Genome-wide copy number analysis in primary breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S31-S35. | 3.4 | 22 |
| 15 | Penetrating Atherosclerotic Ulcer. <i>Surgery Today</i> , 2001, 31, 32-35. | 1.5 | 20 |
| 16 | Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. <i>ESMO Open</i> , 2019, 4, e000476. | 4.5 | 17 |
| 17 | Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 331-341. | 2.5 | 17 |
| 18 | Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System. <i>BioMed Research International</i> , 2015, 2015, 1-11. | 1.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. International Journal of Molecular Sciences, 2019, 20, 984. | 4.1 | 16 |
| 20 | Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 74-84. | 10.7 | 16 |
| 21 | Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. ESMO Open, 2018, 3, e000314. | 4.5 | 15 |
| 22 | Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Science, 2021, 112, 454-464. | 3.9 | 15 |
| 23 | Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast, 2012, 21, 40-45. | 2.2 | 14 |
| 24 | The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients. Npj Precision Oncology, 2017, 1, 6. | 5.4 | 13 |
| 25 | GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. Npj Breast Cancer, 2022, 8, . | 5.2 | 12 |
| 26 | Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence. Radiation Oncology, 2019, 14, 159. | 2.7 | 11 |
| 27 | A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. Cancer Medicine, 2018, 7, 2442-2451. | 2.8 | 10 |
| 28 | Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Medicine, 2018, 7, 3044-3056. | 2.8 | 10 |
| 29 | Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. Pathology Research and Practice, 2020, 216, 152750. | 2.3 | 10 |
| 30 | Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Science, 2022, 113, 1808-1820. | 3.9 | 10 |
| 31 | The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer. Cancer Science, 2022, 113, 2336-2351. | 3.9 | 10 |
| 32 | A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S ¹ for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the Tj ETQ0280 rgBT / Overlock 1 | 3.9 | 10 |
| 33 | Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. Journal of Radiation Research, 2020, 61, 440-446. | 1.6 | 8 |
| 34 | Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). Cancer Science, 2022, 113, 3169-3179. | 3.9 | 8 |
| 35 | Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2019, 174, 103-111. | 2.5 | 7 |
| 36 | Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Japanese Journal of Clinical Oncology, 2020, 50, 3-11. | 1.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. BMC Medicine, 2022, 20, 136. | 5.5 | 7 |
| 38 | A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. Japanese Journal of Clinical Oncology, 2018, 48, 855-859. | 1.3 | 6 |
| 39 | Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports, 2020, 10, 11203. | 3.3 | 6 |
| 40 | Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment Center. Cancer Cell, 2021, 39, 9-10. | 16.8 | 6 |
| 41 | Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report. Journal of Medical Case Reports, 2021, 15, 78. | 0.8 | 6 |
| 42 | Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. Tumor Biology, 2018, 40, 101042831881102. | 1.8 | 5 |
| 43 | Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype. Scientific Reports, 2021, 11, 10858. | 3.3 | 5 |
| 44 | Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Medicine, 2019, 8, 5468-5481. | 2.8 | 4 |
| 45 | Local management after neoadjuvant treatment for breast cancer. Chinese Clinical Oncology, 2020, 9, 34-34. | 1.2 | 4 |
| 46 | Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 13-21. | 2.8 | 4 |
| 47 | Myofibroblastoma of the breast showing rare palisaded morphology and uncommon desmin- and CD34-negative immunophenotype: A case report. Pathology International, 2021, 71, 548-555. | 1.3 | 4 |
| 48 | Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis. BMC Cancer, 2020, 20, 932. | 2.6 | 4 |
| 49 | Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. BMC Cancer, 2022, 22, 36. | 2.6 | 4 |
| 50 | Breast MR Image Fusion by Deformable Implicit Polynomial (DIP). IPSJ Transactions on Computer Vision and Applications, 2013, 5, 99-103. | 4.4 | 3 |
| 51 | Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society. Breast Cancer, 2017, 24, 427-432. | 2.9 | 3 |
| 52 | Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Cancer Science, 2021, 112, 1310-1319. | 3.9 | 3 |
| 53 | Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial). , 2020, , . | | 3 |
| 54 | Assessment of a cancer genomic profile test for patients with metastatic breast cancer. Scientific Reports, 2022, 12, 4813. | 3.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Surgical Management of Metastatic Breast Cancer: A Mini Review. <i>Frontiers in Oncology</i> , 2022, 12, . | 2.8 | 3 |
| 56 | Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 35-35. | 1.2 | 2 |
| 57 | Abstract PD7-05: A multicenter prospective study to predict pathologic complete response by vacuum-assisted breast biopsy based on MRI and US findings after neoadjuvant chemotherapy. <i>Cancer Research</i> , 2022, 82, PD7-05-PD7-05. | 0.9 | 2 |
| 58 | Comment and reply on: Vasohibin-1 and its emerging role in the evolution and progression of systemic tumors besides renal cell carcinomas. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 105-106. | 3.4 | 1 |
| 59 | Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2020, 12, 2633. | 3.7 | 1 |
| 60 | Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study. , 2021, , . | | 1 |
| 61 | Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1026-1026. | 1.6 | 1 |
| 62 | Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12094-e12094. | 1.6 | 1 |
| 63 | Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1075-1075. | 1.6 | 1 |
| 64 | Abstract P5-01-22: Genomic landscape of circulating tumor DNA in early-stage breast cancer. <i>Cancer Research</i> , 2020, 80, P5-01-22-P5-01-22. | 0.9 | 1 |
| 65 | International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1025-1025. | 1.6 | 1 |
| 66 | Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial). , 2020, , . | | 1 |
| 67 | Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC). <i>Breast Cancer</i> , 0, , . | 2.9 | 1 |
| 68 | PO130 CLINICAL UTILITY OF THE EXPRESSION OF HER3, HER4, PTEN AND IGF1R IN HER2-POSITIVE ADVANCED OR METASTATIC BREAST CANCER. <i>Breast</i> , 2015, 24, S66. | 2.2 | 0 |
| 69 | Only a few young patients aged 40 years with “high-risk” breast cancer preserved fertility; report from actual survey in a Japanese cancer hospital. <i>Breast</i> , 2018, 41, S26-S27. | 2.2 | 0 |
| 70 | Characteristics and prognosis of leptomeningeal metastasis in patients with breast cancer. <i>Annals of Oncology</i> , 2019, 30, vi113. | 1.2 | 0 |
| 71 | Response to Sung, Rosenberg, and Yang. <i>Journal of the National Cancer Institute</i> , 2020, 112, 547-548. | 6.3 | 0 |
| 72 | Focused issue “Neoadjuvant/adjuvant treatment for early breast cancer” Chinese Clinical Oncology, 2020, 9, 26-26. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Breast castleman disease. Breast Journal, 2020, 26, 1855-1856. | 1.0 | 0 |
| 74 | Abstract PS1-19: The accuracy of axillary node assessment of ultrasound after neoadjuvant chemotherapy in clinically node positive patients. , 2021, , . | | 0 |
| 75 | Abstract PS2-32: Incidental malignant findings on pre-admission chest computed tomography scan for coronavirus disease screening in patients with breast cancer or other cancers. , 2021, , . | | 0 |
| 76 | Impact of body mass index on the prognosis of Japanese women with operable hormone receptor-positive breast cancer: A single institutional retrospective study.. Journal of Clinical Oncology, 2021, 39, e12547-e12547. | 1.6 | 0 |
| 77 | MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer. Annals of Oncology, 2021, 32, S320. | 1.2 | 0 |
| 78 | Ultrasonographic imaging of invasive ductal carcinoma linked to revision of the histological classification of breast tumors. Choonpa Igaku, 2021, 48, 241-247. | 0.0 | 0 |
| 79 | Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues.. Journal of Clinical Oncology, 2013, 31, 571-571. | 1.6 | 0 |
| 80 | Primary mediastinal germ cell tumor with absent elevation of AFP at recurrence; a case report.. The Journal of the Japanese Association for Chest Surgery, 1997, 11, 186-193. | 0.0 | 0 |
| 81 | Abstract OT1-3-01: Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components. , 2015, , . | | 0 |
| 82 | PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. Journal of Clinical Oncology, 2016, 34, TPS636-TPS636. | 1.6 | 0 |
| 83 | Phase II study on radiofrequency ablation in early breast cancer.. Journal of Clinical Oncology, 2016, 34, e12536-e12536. | 1.6 | 0 |
| 84 | Abstract 4138: Immunological profile of metastatic or recurrent breast cancer patients. , 2016, , . | | 0 |
| 85 | Abstract 3484: Analysis of in situ expression of hormone receptors and proliferation marker at a single cell level in breast cancer tissues. , 2016, , . | | 0 |
| 86 | Utility of Repeat Sentinel Lymph Node Biopsy for cNO Ipsilateral Breast Tumor Recurrence in Patients Initially Treated with Breast-Conserving Surgery and Sentinel Lymph Node Biopsy. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 87 | Abstract P5-01-15: Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer. , 2020, , . | | 0 |
| 88 | Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.. Journal of Clinical Oncology, 2020, 38, 532-532. | 1.6 | 0 |
| 89 | Monitoring of therapeutic efficacy to CDK4/6 inhibitors and early detection of metastatic relapse in breast cancer by ultra-deep sequencing of plasma cell-free DNA.. Journal of Clinical Oncology, 2020, 38, e15544-e15544. | 1.6 | 0 |
| 90 | Abstract A29: Next-generation sequencing of circulating tumor DNA to monitor treatment response to CDK4/6 inhibitors in breast cancer. , 2020, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | A Case of Primary Breast Angiosarcoma in a 20-year-old Woman. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 2432-2436. | 0.0 | 0 |
| 92 | Abstract P1-15-02: Low incidence of hepatitis B reactivation after chemotherapy in Japanese breast cancer patients with resolved HBV. Cancer Research, 2022, 82, P1-15-02-P1-15-02. | 0.9 | 0 |
| 93 | Abstract P4-11-06: Effect of suppressed ovarian function on prognosis of premenopausal obese women with hormone receptor-positive breast cancer: A single-institute retrospective study. Cancer Research, 2022, 82, P4-11-06-P4-11-06. | 0.9 | 0 |